Minimal residual disease in solid tumors: an overview

被引：3

作者：

Ma, Yarui ^{[1
]}

Gan, Jingbo ^{[2
]}

Bai, Yinlei ^{[2
]}

Cao, Dandan ^{[2
]}

Jiao, Yuchen ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Canc Hosp, Beijing 100021, Peoples R China

[2] Genetron Hlth Beijing Co Ltd, Beijing 102206, Peoples R China

来源：

FRONTIERS OF MEDICINE | 2023年 / 17卷 / 04期

关键词：

MRD; solid tumor; CTC; ctDNA; CELL LUNG-CANCER; ACUTE MYELOID-LEUKEMIA; ADVANCED RECTAL-CANCER; LIQUID BIOPSY; BREAST-CANCER; FREE DNA; CLINICAL-IMPLICATIONS; NEOADJUVANT TREATMENT; CIRCULATING DNA; FREE SURVIVAL;

D O I：

10.1007/s11684-023-1018-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Minimal residual disease (MRD) is termed as the small numbers of remnant tumor cells in a subset of patients with tumors. Liquid biopsy is increasingly used for the detection of MRD, illustrating the potential of MRD detection to provide more accurate management for cancer patients. As new techniques and algorithms have enhanced the performance of MRD detection, the approach is becoming more widely and routinely used to predict the prognosis and monitor the relapse of cancer patients. In fact, MRD detection has been shown to achieve better performance than imaging methods. On this basis, rigorous investigation of MRD detection as an integral method for guiding clinical treatment has made important advances. This review summarizes the development of MRD biomarkers, techniques, and strategies for the detection of cancer, and emphasizes the application of MRD detection in solid tumors, particularly for the guidance of clinical treatment.

引用

页码：649 / 674

页数：26